764 related articles for article (PubMed ID: 29704747)
1. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
Li L; Hu S; Chen X
Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
[TBL] [Abstract][Full Text] [Related]
2. Lipid-, Inorganic-, Polymer-, and DNA-Based Nanocarriers for Delivery of the CRISPR/Cas9 system.
Song N; Chu Y; Tang J; Yang D
Chembiochem; 2023 Aug; 24(16):e202300180. PubMed ID: 37183575
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
5. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
6. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
7. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for
Wei T; Cheng Q; Farbiak L; Anderson DG; Langer R; Siegwart DJ
ACS Nano; 2020 Aug; 14(8):9243-9262. PubMed ID: 32697075
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical non-viral vectors exploited for
Rouatbi N; McGlynn T; Al-Jamal KT
Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
[TBL] [Abstract][Full Text] [Related]
9. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
11. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
[TBL] [Abstract][Full Text] [Related]
12. Different Methods of Delivering CRISPR/Cas9 Into Cells.
Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
[TBL] [Abstract][Full Text] [Related]
13. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
14. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
Zhang S; Shen J; Li D; Cheng Y
Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
[TBL] [Abstract][Full Text] [Related]
15. Delivery of gene editing therapeutics.
Kevadiya BD; Islam F; Deol P; Zaman LA; Mosselhy DA; Ashaduzzaman M; Bajwa N; Routhu NK; Singh PA; Dawre S; Vora LK; Nahid S; Mathur D; Nayan MU; Baldi A; Kothari R; Patel TA; Madan J; Gounani Z; Bariwal J; Hettie KS; Gendelman HE
Nanomedicine; 2023 Nov; 54():102711. PubMed ID: 37813236
[TBL] [Abstract][Full Text] [Related]
16. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
[TBL] [Abstract][Full Text] [Related]
17. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
Wan T; Ping Y
Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in stimuli-responsive polymeric carriers for controllable CRISPR/Cas9 gene editing system delivery.
Ma P; Wang Q; Luo X; Mao L; Wang Z; Ye E; Loh XJ; Li Z; Wu YL
Biomater Sci; 2023 Jul; 11(15):5078-5094. PubMed ID: 37282836
[TBL] [Abstract][Full Text] [Related]
19. Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors.
Li L; He ZY; Wei XW; Gao GP; Wei YQ
Hum Gene Ther; 2015 Jul; 26(7):452-62. PubMed ID: 26176432
[TBL] [Abstract][Full Text] [Related]
20. Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing.
Tang H; Zhao X; Jiang X
Adv Drug Deliv Rev; 2021 Jan; 168():55-78. PubMed ID: 32147450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]